相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
J. Drappatz et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance
Cynthie Wong et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2012)
Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers
Sarah C. Baumgarten et al.
MOLECULAR ENDOCRINOLOGY (2012)
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Chandra R. Tate et al.
BREAST CANCER RESEARCH (2012)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Inflammation and Increased Aromatase Expression Occur in the Breast Tissue of Obese Women with Breast Cancer
Patrick G. Morris et al.
CANCER PREVENTION RESEARCH (2011)
Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland
Kotha Subbaramaiah et al.
CANCER PREVENTION RESEARCH (2011)
Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
Gauri J. Sabnis et al.
CANCER RESEARCH (2011)
Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment
Ryohei Furumai et al.
CANCER SCIENCE (2011)
Molecular effects of oestrogen deprivation in breast cancer
William R. Miller et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
Cornelis J. H. van de Velde et al.
LANCET (2011)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
Meredith M. Regan et al.
LANCET ONCOLOGY (2011)
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
W. Song et al.
LEUKEMIA (2011)
Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy
Mette L. Josefsson et al.
BREAST (2010)
BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells
Ruchi Nehra et al.
FASEB JOURNAL (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression
Shiuan Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
Melissa J. LaBonte et al.
BMC MEDICAL GENOMICS (2009)
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
Michael Dickinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
Scott Thomas et al.
CANCER LETTERS (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines
Michael B. Prystowsky et al.
JOURNAL OF PATHOLOGY (2009)
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Anna Scuto et al.
BLOOD (2008)
NF-kappa B genes have a major role in Inflammatory Breast Cancer
Florence Lerebours et al.
BMC CANCER (2008)
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor
Selma Masri et al.
CANCER RESEARCH (2008)
Nuclear factor-kappa B1: Regulation and function
Silvia Gaspar Pereira et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
What do we know about the mechanisms of aromatase inhibitor resistance?
Shiuan Chen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2006)
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
D. S. Basseres et al.
ONCOGENE (2006)
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κB by tumor necrosis factor-α receptor-1 down-regulation
Gabriele Imre et al.
CANCER RESEARCH (2006)
Acetylation of Stat1 modulates NF-κB activity
OH Krämer et al.
GENES & DEVELOPMENT (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
The NFκB pathway and endocrine-resistant breast cancer
Y Zhou et al.
ENDOCRINE-RELATED CANCER (2005)
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-jun n-terminal kinase 1 activation
Y Dai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers
YM Zhou et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding
J Hu et al.
MOLECULAR CANCER RESEARCH (2005)
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway
MW Mayo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Selective activation of NF-κB subunits in human breast cancer:: potential roles for NF-κB2/p52 and for Bcl-3
PC Cogswell et al.
ONCOGENE (2000)
分享论文
